ICCC FY 2018 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+5.3% YoY

Gross Profit

$5M47.3% margin

Operating Income

-$1M-13.2% margin

Net Income

-$2M-21.1% margin

EPS (Diluted)

$-0.42

Cash Flow

Operating Cash Flow

-$373,404

Free Cash Flow

-$2M

Stock-Based Comp.

$344,016

Balance Sheet

Total Assets

$33M

Total Liabilities

$11M

Stockholders' Equity

$22M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$10M	+5.3%
Gross Profit	$5M	$5M	-0.5%
Operating Income	-$1M	-$243,000	-495.5%
Net Income	-$2M	-$168,000	-1282.1%